In a striking new study, the anti-obesity drug tirzepatide, known as Mounjaro and Zepbound, not only triggered significant weight loss in obese mice but also slashed breast cancer tumor growth. The research, presented at ENDO 2025, links body fat reduction to better cancer outcomes, suggesting that these next-generation weight-loss drugs might offer unexpected benefits beyond metabolic health. With traditional dieting often falling short, this dual-action approach could reshape how doctors tackle obesity-related cancers.
from Top Health News -- ScienceDaily https://ift.tt/Iu64dGN
No comments:
Post a Comment